Navigation Links
Verenium Announces Signing of Lease for New Office and Lab Space
Date:6/29/2011

SAN DIEGO, June 29, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced the signing of a lease agreement for new office and laboratory space in the Torrey Pines area of San Diego, CA.  The lease is targeted to commence in the summer of 2012 following the build out of the new facility and the expiration of Verenium's current sublease, which was negotiated as part of the sale of its cellulosic biofuels business in July of 2010 to BP Biofuels North America.

"We are very excited to have identified a new location for Verenium that will accommodate our current and future growth," said James Levine, President and Chief Executive Officer at Verenium. "It was also important to us to remain in San Diego and we are particularly happy to be relocating to Torrey Pines, one of the area's most important centers for innovation which already houses some of the world's leading biotechnology companies and life sciences institutes.  We are pleased to be able to capitalize on a favorable real estate market and begin plans for building a customized space to support growing our business in the San Diego area."

About VereniumVerenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

Forward-Looking Statements for VereniumStatements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to
'/>"/>

SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes
2. Verenium Receives CLARUS Award at MDB Capitals Bright Lights Conference 2011
3. Verenium to Present at Upcoming Conferences
4. Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing
5. Verenium to Present at MDB Capital Groups Bright Lights Conference
6. Verenium Announces Debt Repurchase
7. Worlds Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Vereniums Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval
8. Verenium Corporation to Announce Fourth Quarter and Year-End 2010 Financial Results
9. Verenium to Present at Jefferies 11th Global Clean Technology Conference
10. Verenium Announces Favorable Outcome of Capital Ventures International Lawsuit
11. Verenium to Present at Piper Jaffray Sixth Annual Clean Technology & Renewables Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 30, 2015 PMG Research, Benchmark ... announce the formation of VaxCorps, a network of ... in the conduct of vaccine trials in healthy ... sites have successfully conducted over 500 phase I-III ... and pandemic influenza as well as a vast ...
(Date:3/30/2015)... , March 30, 2015  New Jersey Health ... projects in the state of New Jersey ... round of grant funding, announced James M. Golubieski ... Health Foundation Research Grants program, an additional $500,000 will ... to fund early stage research projects that demonstrate exciting ...
(Date:3/30/2015)... 30, 2015    Intrexon Corporation (NYSE: ... and Merck Serono, the biopharmaceutical business of Merck ... announced an exclusive strategic collaboration and license agreement ... (CAR-T) cancer therapies. This collaboration advances Merck Serono,s ... modulate the immune system,s natural ability to fight ...
(Date:3/30/2015)... 2015  Naldemedine, an investigational peripherally acting mu-opioid ... Co., Ltd., met its primary and secondary endpoints ... the treatment of opioid-induced constipation (OIC) in adult ... Study results showed that naldemedine (0.2 mg tablet ... of spontaneous bowel movement (SBM) compared with placebo ...
Breaking Biology Technology:PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2New Jersey Health Foundation Announces An Additional $1 Million To Fund Innovation and Research Grants in New Jersey 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
... May 17 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. ( ... company specialized in oncology and endocrinology, today announced that ... product designation from the Committee for Orphan Medicinal Products ... AEZS-108 for the treatment of ovarian cancer. AEZS-108, the ...
... , May 17 Soligenix, Inc. (OTC Bulletin Board: SNGX) ... results for the first quarter of 2010. , ... Soligenix,s revenues for the first quarter of 2010 ... the first quarter of 2009. The decreased revenues were primarily a result ...
... Sigma- Aldrich announces the retirement of David Julien , President – ... on his current role in January 2009 .  He served as President ... to January 2009 and before that in a number of senior ... , , , ...
Cached Biology Technology:Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency 2Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency 3Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments 2Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments 3Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments 4Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments 5Sigma-Aldrich (Nasdaq: SIAL) Announces Executive Management Changes: Retirement of David Julien and Promotion of Joseph Porwoll 2
(Date:3/16/2015)... 16, 2015 Between 16 ... present groundbreaking innovations in biometric identification at the ... .      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ... is well at the forefront: the company,s all ... in Germany . BiometricGate is ...
(Date:3/12/2015)... 2015 Beta Systems today ... access management (IAM) solution for a fixed price ... System,s new IAM package, customers benefit from the ... multiple IAM implementations across different industries. The new ... as any necessary services and consulting. It spans ...
(Date:3/11/2015)... 11, 2015   The Sync Project™ ... scientifically measure and harness music to improve health. ... and objective measurements of physiology, enabling the study ... in large populations. It is designed for medical ... perform rigorous studies and accelerate the discovery of ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
... ITHACA, NY Commercial apple growers in the northeastern ... and insect invasions to tree nutrition and crop load. ... of integrated fruit production (IFP) and organic fruit production ... alternative markets. In a recent issue of HortScience ...
... Today,s most common cultivated strawberry, the familiar Fragaria x vananassa ... a chance hybridization of two wild strawberry species in Europe ... characteristics of both species, including the larger, firmer fruit of ... fruit of F. virginiana . The fact that ...
... the most important fruit trees in the world. Citrus has ... than 4,000 years. Until now, however, the exact genetic origins ... ), lemon ( C. limon ), and grapefruit ( C. ... from China has published a study in the Journal of ...
Cached Biology News:Integrated, organic production systems evaluated for 'liberty' apple 2New research expands genetic base of cultivated strawberry 2Genetic origin of cultivated citrus determined 2
Sprague-Dawley rats, 7-8 weeks old, mixed gender; tissue is collected fresh, frozen on dry ice within minutes of sacrifice and stored at -20C; individual tissue weight approx. 0.05 gram....
...
Contains L-glutamine...
EMBP (FL-222)...
Biology Products: